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ABSTRACT
The transcription elongation factor 5,6-dichloro-1-
b-D-ribofuranosylbenzimidazole (DRB) sensitivity-
inducing factor (DSIF) regulates RNA polymerase II
(RNAPII) processivity by promoting, in concert
with negative elongation factor (NELF), promoter-
proximal pausing of RNAPII. DSIF is also reportedly
involved in transcriptional activation. However, the
role of DSIF in transcriptional activation by
DNA-binding activators is unclear. Here we show
that DSIF acts cooperatively with a DNA-binding
activator, Gal4-VP16, to promote transcriptional
activation. In the absence of DSIF, Gal4-VP16-
activated transcription resulted in frequent pausing
of RNAPII during elongation in vitro. The presence of
DSIF reduced pausing, thereby supporting Gal4-
VP16-mediated activation. We found that DSIF
exerts its positive effects within a short time-frame
from initiation to elongation, and that NELF does
not affect the positive regulatory function of DSIF.
Knockdown of the gene encoding the large subunit
of DSIF, human Spt5 (hSpt5), in HeLa cells reduced
Gal4-VP16-mediated activation of a reporter gene,
but had no effect on expression in the absence
of activator. Together, these results provide evi-
dence that higher-level transcription has a stronger
requirement for DSIF, and that DSIF contributes
to efficient transcriptional activation by preventing
RNAPII pausing during transcription elongation.
INTRODUCTION
Transcription elongation plays an important role in gene
expression in both prokaryotes and eukaryotes. In recent
years, several lines of evidence have indicated that
transcription elongation is not only a rate-limiting step
in gene expression, but also a dynamic and highly
regulated process that also impacts downstream events,
such as mRNA processing, and RNA surveillance and
export (1,2). The importance of such regulation is illus-
trated by the discovery that a variety of elongation factors
contribute to development, diﬀerentiation and disease
progression (3). Intensive study of transcription elonga-
tion factors has identiﬁed a number of regulatory
mechanisms by which RNAPII eﬃciently elongates
RNA, regardless of impediments (2,3).
DSIF is a heterodimer protein complex composed of
Spt4 and Spt5, and is conserved among eukaryotes. DSIF
exerts both negative and positive eﬀects on elongation by
directly binding to RNAPII through the KOW domain of
Spt5 (4–6). DSIF negatively regulates transcription by
acting in concert with NELF to mediate promoter proxi-
mal pausing of RNAPII (7,8). The positive regulatory
activity of DSIF has been shown to stimulate transcrip-
tion processivity through an as-yet undeﬁned mechanism.
DSIF progresses along with RNAPII to downstream
regions of transcribed genes, and phosphorylation of the
C-terminal repeat (CTR) region of Spt5 plays a key role in
converting DSIF from a repressor to a positive regulator
(9–13), suggesting possible mechanisms of regulation of
the activator functions of DSIF.
Analysis of Drosophila embryo polytene chromosomes
using immunostaining demonstrated that Spt5 localizes
to active sites of transcription, and co-localizes with the
phosphorylated form of the large subunit of RNAPII
during elongation (11,14). Saunders et al. (15) reported
that Drosophila Spt5 tracks with the RNAPII elongation
complex along chromatin in vivo. In addition to its inter-
action with RNAPII, genetic and biochemical evidence
indicates that DSIF also associates with other components
of the transcriptional machinery, such as TFIIF, TFIIS,
CSB, Spt6, FACT, Chd1 and the Paf complex, and with
factors involved in mRNA maturation and surveillance,
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ase, and the nuclear exosome (2,16–19). Although the
biochemical characteristics of DSIF are consistent with
its function as a general transcription elongation factor,
recent studies suggest that it also has a role in the
regulation of development, and in gene-speciﬁc regulation.
For example, zebraﬁsh carrying a point mutation or
deletion of spt5 display a pleiotropic but highly neuron-
speciﬁc pattern of defects, suggesting the involvement
of DSIF in development (20). In Drosophila embryos, an
Spt5 missense mutation has locus-speciﬁc eﬀects on tran-
scription, suggesting that Spt5 aﬀects gene expression
selectively (21). Moreover, microarray analysis of both
zebraﬁsh and human Spt5 knockdown cells showed
changes in expression of only a small subset of genes
(unpublished data).
The above discrepancies may be explained by assuming
that there is a stronger requirement for DSIF during high-
levels of transcriptional activity (22). This idea is sup-
ported by studies of hsp, c-fos and HIV genome activation.
Induction of heat shock gene transcription causes massive
recruitment of Spt5 to hsp loci (11). Drosophila and
zebraﬁsh carrying Spt5 null alleles show defects in their
heat shock response (21,23). Knockdown of DSIF in
human cells causes a signiﬁcant defect in c-fos transcrip-
tional activation in response to epidermal growth factor,
while having a negligible eﬀect on c-fos expression under
basal conditions (9). DSIF has also been implicated in
Tat-mediated transactivation of HIV genome transcrip-
tion. Tat is a viral activator that binds cis-acting TAR
elements in nascent RNAs, and stimulates elongation of
HIV genes. Knockdown of Spt5 in human cells decreases
Tat-mediated transactivation and HIV-1 replication, but
does not signiﬁcantly aﬀect cell viability (24). DSIF
cooperates with Tat by preventing premature RNA release
at terminator sequences, suggesting a possible mechanism
of action of DSIF in regulating HIV transcription (25).
The transcription of most cellular genes, however, is
thought to be activated by DNA-binding activators. It is
not clear whether DSIF exerts similar eﬀects when
working with DNA-binding activators.
In this report, we used in vitro transcription assays
of Gal4-VP16, a DNA-binding transcriptional activator,
to investigate the requirement for DSIF in transcriptional
activation. Gal4-VP16 interacts with general transcription
factors and the Mediator complex to stimulate initiation
(26–29). It has also been implicated in the stimulation of
elongation, probably through its interaction with TFIIH
(30). We demonstrated that in the absence of DSIF, Gal4-
VP16-mediated transcriptional activation causes more
pausing during elongation than that which occurs during
basal transcription. DSIF supported full transcriptional
activation by reducing pausing of RNAPII during
elongation. We also showed that transcriptional activity
requires DSIF in vivo. In cultured HeLa cells, Gal4-VP16-
induced expression of a reporter gene was signiﬁcantly
decreased upon Spt5 knockdown. In the absence of the
VP16 activation domain, reporter gene expression was
at basal levels, and was not aﬀected substantially by
Spt5 knockdown. Co-expression of the DNA-binding
competitor of Gal4-VP16, Gal4DBD, which blocked
transcriptional activation of the reporter gene, diminished
the requirement for DSIF. These results suggest that DSIF
regulates transcription elongation in response to tran-
scriptional activation by DNA-binding activators. In
addition, we showed that DSIF exerts its positive eﬀect
within a short time-frame from initiation to elongation,
and that NELF is not involved in the positive regulatory
eﬀect of DSIF.
MATERIALS AND METHODS
Preparation ofrecombinant proteins
An expression plasmid encoding recombinant Histidine
(His)-tagged DSIF (His-DSIF) was constructed by com-
bining sequences for His-tagged human Spt4 (hSpt4) and
hSpt5 in a single expression plasmid. The co-expression
construct was generated using pET-hSpt4 and pET-hSpt5
(4). pET-hSpt5 was digested by AatII and NdeIt o
generate the hSpt5 coding sequence fragment. pET-14b
was digested using NcoI and AatII to eliminate the His-tag
sequence, and then ligated to the hSpt5 fragment to
generate pT7hSpt5. pET-hSpt4 was digested using SphI
and BamHI and inserted into pT7hSpt5 that had been
digested with SphI and BglII.
Recombinant His-DSIF (His-hSpt4/hSpt5) was
expressed in E. coli BL21-CodonPlus (DE3)-RIL
(Stratagene). After induction with 1mM IPTG for 4h at
308C, cells were harvested and lysed, and then lysates were
loaded onto a Ni-NTA column (Qiagen). Recombinant
His-DSIF was puriﬁed under native conditions according
to the protocols in the QIAexpressionist handbook
(Qiagen). Proteins eluted from the Ni-NTA column were
loaded onto a 1ml Mono Q column and eluted with
a linear gradient of 100 to 1000mM HGKEDP [20mM
HEPES (pH 7.9), 20% glycerol, 100–1000mM KCl,
0.2mM EDTA, 1mM DTT, 1mM PMSF]. The fractions
were analyzed by SDS–polyacrylamide gel electrophoresis
(PAGE), and fractions containing recombinant His-DSIF
were dialyzed against 100mM HGKEDP, and stored
at  808C until use. Coexpression of hSpt4 and hSpt5 was
done to address the formation of insoluble aggregates,
and avoid the denaturation/renaturation process used in
a previous puriﬁcation protocol (4).
His-GAL4 (1–94)-VP16 (413–490) was expressed in
E. coli and puriﬁed as described by Reece et al. (31). Flag-
NELF was puriﬁed as previously described (8). Cdk9 and
Cyclin T1 subunits of P-TEFb were coexpressed in Sf9
cells with baculoviral vectors and puriﬁed as previously
described (9).
Construction ofthe plasmid pG5MLPDG
The plasmid pG5MLPDG was generated by replacing
the G-free cassette of pG5MLP (32) with the double
G-free cassettes fragment from the plasmid pSLG402 (9).
Invitro transcription assays
Concentrated P1.0 fractions were prepared as described
previously (33,34). In vitro transcription reactions using
the concentrated P1.0 fraction and plasmid DNA tem-
plates were carried out as described previously (9,34).
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12.5ml reaction mixtures containing 125ng DNA (32)
and the concentrated P1.0 fraction were prepared in the
presence or absence of recombinant DSIF and Gal4VP16
in TRX buﬀer [25mM Tris–HCl (pH 7.9), 10% (v/v)
glycerol, 50mM KCl, 0.5mM DTT and 0.5mM EDTA].
Reactions were incubated for 40min at 308C. NTPs and
80mM3 0-OMe-GTP in TRX buﬀer were then added, and
the mixture was incubated for the indicated times. Where
indicated, 1.5mM each of ATP, UTP and CTP were
added and reactions were incubated for an additional
period of time. In Figure 3D, pG5MLPDG was used as
a template. Transcription reaction was allowed to proceed
for 20min in the presence of 60mM ATP, 600mM GTP,
600mM CTP, 5mM UTP and 5mCi of [a-
32P]UTP
(800Ci/mmol). G-free RNA fragments derived from
transcripts were isolated after RNase T1 treatment,
deproteinized, precipitated with ethanol and analyzed
using 8% acrylamide denaturing gels, as previously
described (4). In Figures 1F and 3E, transcripts were
quantiﬁed by a phosphorimager (Molecular Dynamics,
Storm 860).
Immunodepletion of P-TEFb from concentrated
P1.0 fraction
Immunodepletion was performed by incubating 100ml
concentrated P1.0 fraction containing 0.2% NP-40 and
350mM KCl with 3.5mg of anti-CDK9 antibodies at 48C
for 30min, followed by incubation with 30 ml protein-G
Sepharose beads (GE Healthcare). After removal of the
beads, the fraction was incubated with 3.5mg fresh anti-
CDK9 antibodies again for 30min at 48C, followed by
three rounds of incubation with 30ml protein-G Sepharose
beads. The depleted fraction was dialyzed against 100mM
HGKEDP prior to analysis in Western blotting and
in vitro transcription assays.
Luciferase assay
The following sequences were inserted into pBluescript
SK+ (Stratagene) carrying the mouse U6-promoter (9) to
generate the shRNA expression plasmids pBS-U6-hSpt5
(No. 1) and pBS-U6-hSpt5 (No. 2), respectively: U6-P160-
1 (No. 1), 50-GAACTGGGCGAGTATTACAttcaagaga
TGTAATACTCGCCCAGTTCtt-30 [sequences in upper-
case correspond to nucleotides (nts) 406–424 of hSpt5
mRNA]; U6-P160-2 (No. 2), 50-GGCTATATCGGTG
TGGTGAttcaagagaTCACCACACCGATGTAGCCtt-30
(sequences in uppercase correspond to nts 2155–2173 of
hSpt5 mRNA.
The reporter gene plasmid carried a HindIII–HindIII
DNA fragment (420bp) derived from the yeast GAL1–
GAL10 promoters, the adenovirus early region 4 (E4)
promoter sequence ( 33 to +9), and the luciferase gene
derived from the PicaGene PGV-B plasmid (Toyo-ink).
HeLa S3 cells were maintained in DMEM (Invitrogen)
supplemented with 10% fetal calf serum and L-glutamate.
Cells (8 10
4 cells) were plated in 24-well plates and
transfected with a total of 552ng of DNA [50ng of
reporter plasmid, 2ng of pCG-GAL4DBD (1–94)
or pCG-GAL4 (1–94)-VP16 (413–490), kindly provided
by Dr W. Herr (35) and 500ng of pBluescript carrying
the U6-promoter] using Lipofectamine 2000 (Invitrogen).
In Figure 5B, the cells were harvested at the indicated
times post-transfection. In Figure 5C, the indicated
amounts of Gal4DBD expression plasmid were used.
HeLa cells were transferred to fresh medium in a 12-well
plate 24h post-transfection and harvested 72h post-
transfection and luciferase activity was measured.
Luciferase activity from triplicate experiments was nor-
malized to protein amounts; data represents normalized
values.
RESULTS
DSIF and Gal4-VP16have distinct roles instimulating
transcription
We employed an in vitro transcription assay developed
previously in our lab to analyze the stimulatory activity of
DSIF and Gal4-VP16. The system was based on previous
work showing that DSIF stimulated elongation under
conditions of limited nucleotide triphosphates (NTPs) (4).
A phosphocellulose eluate (P1.0) derived from HeLa cell
nuclear extracts (NEs) was generated, as previously
described, containing RNAPII, general transcription
factors and P-TEFb, but lacking DSIF and NELF
(Figure 1A). A supercoiled plasmid DNA template
containing ﬁve Gal4-binding sites upstream of an adeno-
virus major late promoter (MLP), and a 380-bp G-free
cassette downstream of the promoter, was used as the
template (Figure 1B).
In the absence of DSIF, synthesis of full length
transcripts was eﬃciently carried out in P1.0 in the pre-
sence of 60mM ATP, 600mM CTP, 5mM UTP and 5mCi
[a
32P] UTP (Figure 1C, lane 1). Reducing the concentra-
tions of UTP and CTP resulted in ineﬃcient synthesis of
the full length transcripts, and the appearance of short
transcripts ranging in size from 100 to 200nt (Figure 1C,
lanes 2 to 4). Further reducing the concentrations of UTP
and CTP to 1mM signiﬁcantly decreased the amount of
shorter transcripts (Figure 1C, lane 5). This was consistent
with the previous results obtained using a diﬀerent
template (4). In order to determine whether these results
reﬂected transcriptional pausing or termination, the
reaction was carried with the addition of a 1.5mM ATP,
CTP and UTP chase (Figure 1C, lanes 6 to 10). Under
these conditions, short transcripts were extended and
gradually disappeared, and full-length transcripts
appeared after 2min incubation with the high concentra-
tions of NTPs. These results suggested that the short
transcripts generated in this assay resulted from pausing
of RNAPII, rather than transcription termination, and
that under conditions of limited concentrations of NTPs,
RNAPII is prone to pausing in vitro.
Upon the addition of increasing amounts of recombi-
nant histidine-tagged DSIF (His-DSIF) (Figure 1D) to the
reaction, there was a reduction in short transcripts, and
full-length transcripts were eﬃciently produced
(Figure 1E, lanes 1 to 4). This result was also consistent
with the previous results (4), and suggested that DSIF
stimulates elongation by reducing pausing. In contrast to
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Figure 1. Transcription elongation pauses in low concentrations of nucleotide precursors. (A) Western blot analysis showed that the concentrated
P1.0 fraction contains RNAPII, general transcription factors, Mediator, and P-TEFb, but lacks DSIF and NELF. (B) Schematic representation
of pG5MLP, showing the ﬁve Gal4-binding sites followed by the adenovirus major late promoter (MLP), and a 380bp G-free cassette.
(C) Transcription assays were carried out using P1.0 and pG5MLP as the template, with 60mM ATP, 5mCi of [a-
32P]UTP (800Ci/mmol) and the
indicated concentrations of UTP and CTP. Chase reactions were carried out after 15min of initiation/elongation, by further incubation for the
indicated times with 1.5mM ATP, CTP and UTP, as shown schematically in the lower diagram. (D) Silver staining of puriﬁed recombinant
His-DSIF and His-Gal4-VP16 proteins. (E) In vitro transcription assays were carried out using P1.0 and pG5MLP as the template, in the absence
or presence of His-DSIF (7.5ng in lane 2; 30ng in lane 3; 120ng in lane 4) and His-Gal4-VP16 (50ng in lane 5; 100ng in lane 6; 150ng in lane 7), as
shown schematically in the lower diagram. Numbers to the left indicate the positions of markers (nucleotides). (F) Products in panel E was quantiﬁed
by a phosphorimager, and the amounts (in arbitrary units) were plotted against the length. The numbers at the top and the bottom indicate the
positions of markers (nucleotides). The numbers to the right correspond to the lane numbers in panel E.DSIF, His-Gal4-VP16 (Figure 1D) increased the synthesis
of full-length transcripts as well as short transcripts of
various lengths (Figure 1E, lanes 5 to 7). Quantiﬁcation of
the transcripts using a phosphorimager (Figure 1F)
revealed that the addition of His-DSIF resulted in a
3- to 6-fold increase in the amount of full-length
transcripts and a concomitant decrease in the amount
of shorter transcripts. Transcripts of 120nt, for example,
decreased by approximately 2.5-fold (Figure 1F, lanes 1
and 4). The addition of His-Gal4-VP16 resulted in a 2- to
8-fold increase in the amount of full-length transcripts, as
well as an increase in the amount of shorter transcripts
(i.e. 120nt transcripts increased 3-fold, Figure 1F, lanes 1
and 7). These results suggested that DSIF and Gal4-VP16
regulate diﬀerent steps of transcription.
DSIFand Gal4-VP16 actin acooperative manner
To determine whether the short transcripts generated
in the presence of Gal4-VP16 were the products of
paused RNAPII, we performed a chase experiment in
the presence of Gal4-VP16 (Figure 2A). Short tran-
scripts generated in the presence of His-Gal4-VP16
disappeared after the 2-min chase period (Figure 2A,
lanes 3 and 4), demonstrating that they were due to paused
RNAPII.
To study the eﬀect of DSIF and Gal4-VP16 in more
detail, we varied the incubation time after NTP addition
(Figure 2B). When neither DSIF nor Gal4-VP16 was
present, there was a negligible diﬀerence between the
products of an 11.5- and 15-min reaction, wherein
RNAPII paused between nts +100 and +200. After a
30-min reaction, more transcripts of various sizes, includ-
ing full-length transcripts, were generated (Figure 2B,
lanes 1, 5 and 9). These results suggested that longer
incubation times permit more initiation events. In the
absence of DSIF, synthesis of full-length transcripts took
over 15min, whereas in the presence of DSIF, less than
11.5min were needed (Figure 2B, lane 2). More full-length
products appeared after 30min incubation in the presence
of DSIF compared to the absence of DSIF, which was
likely due to a higher level of processivity (Figure 2B,
lanes 2, 6 and 10). When His-Gal4-VP16 was added to the
reaction instead of His-DSIF, in an 11.5-min reaction,
transcripts were generated in the size range of 100–200nt;
full-length transcripts ﬁrst appeared after 15min, which
was later than their appearance in the DSIF-containing
reactions (Figure 2B, lanes 3, 7 and 11). In addition,
in contrast to DSIF-containing reactions, small-sized
transcripts increased signiﬁcantly over time, suggesting
that in the presence of His-Gal4-VP16, initiation occurred
eﬃciently, and the elongation step was rate-limiting.
Concomitant addition of His-DSIF and His-Gal4-VP16
increased the amount of full-length products compared to
addition of either His-DSIF or His-Gal4-VP16 alone at all
time points (Figure 2B, lanes 4, 8 and 12), and the size
distribution of the transcripts was more like that seen in
reactions containing His-DSIF, rather than His-Gal4-
VP16. These results showed that DSIF and Gal4-VP16 act
cooperatively to stimulate a high-level of transcriptional
activation. When a DNA template lacking Gal4-binding
sites was used in the reaction, there was no stimulation of
transcription (data not shown). Together, these results
indicated that the cooperative function Gal4-VP16 and
DSIF requires that both molecules act on the same DNA
molecule.
Prior incubation of DSIF withtranscription complex
is criticalto its positive activity
DSIF associates with its target genes upon transcriptional
induction, such as during heat-shock induction in
Drosophila (11), possibly through recruitment by activa-
tors to elongation complexes. On the other hand, we have
shown here that DSIF reduces transcriptional pausing
equally well in the presence or absence of an activator,
suggesting that activators may be dispensable for the
recruitment and function of DSIF. We next examined the
mechanism of recruitment of DSIF to elongation com-
plexes, and whether activators have any eﬀect on its
activity.
As shown earlier (Figure 1C), when high concentrations
of cold NTP were added 15min after transcription was
allowed to initiate, paused transcripts were eﬃciently
extended (Figure 3A, lanes 8 to 10). When DSIF was
instead added at the same time point, no stimulatory eﬀect
was observed (Figure 3A, lanes 5 to 7), suggesting that
DSIF is unable to exert its stimulatory activity on the
elongation complex at this stage. We therefore changed
the time points at which DSIF was added to the reaction,
to determine the stage at which DSIF exerted its positive
eﬀect (Figure 3B). Compared to reactions in which DSIF
was added 40min before the addition of NTPs (Figure 3B,
lane 1), the positive activity of DSIF was attenuated when
it was added concomitantly with NTPs, and was abolished
when added afterward (Figure 3B, lanes 2 to 6). This
indicated that DSIF exerts its positive eﬀect within a short
window of time from initiation to elongation. The
presence of Gal4-VP16 increased the amount of tran-
scripts, but did not change the eﬀect of DSIF, indicating
that the activator does not alter the time-frame in which
DSIF functions (Figure 3B, lanes 7 to 12).
Although DSIF is thought to regulate transcription
elongation, the above result suggests that DSIF may in
fact aﬀect a step before elongation, such as promoter
clearance. To examine this possibility, we carried out
transcription reactions by using a DNA template that
produces long transcripts containing double G-free
cassettes (Figure 3C). RNase T1 treatment of the
transcripts allows simultaneous quantiﬁcation of promoter-
proximaland-distalregions.Thelevelofpromoter-proximal
transcripts can generally be equated with the level of
transcription initiation, while the ratio of promoter-distal
to promoter-proximal transcripts reﬂects the eﬃciency of
elongation. As reported previously (9,20), DSIF led an
increase of eﬃciency of transcription elongation by
3.8-fold, while it had negligible eﬀect on the synthesis
of promoter-proximal transcripts (Figure 3D, lanes 1
and 2), suggesting that DSIF does not inﬂuence
transcription initiation. On the other hand, Gal4-VP16
activated the synthesis of both promoter-proximal and
-distal transcripts with only a marginal eﬀect on the
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mainly aﬀects transcription initiation (Figure 3D, lane
3). Gal4-VP16 and DSIF showed selective eﬀects on
initiation and elongation, respectively, even at the highest
concentrations examined (data not shown). Collectively,
these results are consistent with the previous view and
suggest that Gal4-VP16 and DSIF together enhance
overall transcription by accelerating diﬀerent steps in
transcription.
NELF does notaffect thepositive activity of DSIF
It has been established that DSIF negatively regulates
transcription elongation by acting in concert with NELF
(7,8). In contrast, how DSIF stimulates transcription
elongation is largely unknown except that P-TEFb-
mediated phosphorylation of the Spt5 subunit of DSIF
is responsible for converting DSIF from a repressor to
a positive regulator (9). One possible model is that
promoter-proximal pausing leads to processive elongation
thereafter, possibly serving as a checkpoint for this
subsequent process. We therefore examined the roles of
NELF and P-TEFb in the positive activity of DSIF.
We puriﬁed Flag-epitope-tagged NELF (FLAG-NELF)
(Figure 4A) from a Flag-NELF-E-expressing HeLa cell
line derivative, and added it to the transcription assay
(Figure 4B). There was no appreciable eﬀect of addition of
NELF on DSIF-activated transcription, or basal tran-
scription levels in the absence of DSIF (Figure 4B, lanes
3 to 6). In the presence of DRB, an inhibitor of the
P-TEFb kinase, the positive activity of DSIF was
signiﬁcantly inhibited (Figure 4B, lanes 2 and 8), suggest-
ing that P-TEFb is critical for the positive regulatory eﬀect
of DSIF. Addition of NELF resulted in a much stronger
inhibitory eﬀect and the generation of transcripts of less
than 150nt (Figure 4B, lanes 9 and 10). Based on the
results of previous studies, this eﬀect is likely due to
promoter-proximal pausing induced by NELF and DSIF
upon inhibition of P-TEFb activity by DRB (4,36).
Consistent with the previously published results (36),
NELF was unable to induce such pausing in the absence
of DSIF, even in the presence of DRB (Figure 4B, lanes 5,
6, 11 and 12). These results indicated that the positive
activity of DSIF is dependent on P-TEFb and indepen-
dent of NELF.
To further conﬁrm the above results, we depleted
P-TEFb from P1.0 fraction (Figure 4C) and added it
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Figure 2. DSIF and Gal4-VP16 stimulate transcription cooperatively. (A) Transcription assays were carried out as described for Figure 1E.
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Figure 3. DSIF does not exert its positive activity on late transcription complexes that are paused downstream. (A) In vitro transcription assays were
carried out using P1.0 and pG5MLP as the template, as shown in the lower diagram. After a 40-min pre-incubation step, 60mM ATP, 10mM CTP,
1mM UTP and 5mCi [a-
32P]UTP (800Ci/mmol) were added to initiate transcription, and reactions were allowed to proceed for 15 to 20min. In lanes
5 to 7, 7.5ng of His-DSIF was added after 15min of initiation/elongation, and reactions were further incubated for 1, 2 and 5min, respectively.
In lanes 8 to 10, a chase experiment was carried out as described for Figure 1C. The incubation time after the ﬁrst 15-min initiation/elongation is
labeled at the top. (B) In vitro transcription assays were carried out as described for panel A, except that 7.5ng of His-DSIF was added at the
indicated time points, as shown in the lower diagram. His-Gal4-VP16 was added together with P1.0 to the reactions in lanes 7 to 12. (C) Schematic
representation of the plasmid pG5MLPDG. The template produces transcripts containing two G-free cassettes under the control of the same
promoter and GAL4-binding sites as in pG5MLP. The promoter-proximal and -distal G-free cassettes of 84 and 376bp in length are located 40 and
1522bp downstream of the transcription start site, respectively. (D) In vitro transcription reaction was carried out using pG5MLPDG as a DNA
template with concentrated P1.0. His-DSIF (7.5ng) and His-Gal4-VP16 (150ng) were added as indicated. Arrows indicate promoter-proximal
(40–124) and -distal (1512–1888) fragments of transcripts. (E) The promoter-proximal and -distal fragments of transcripts in D were quantiﬁed using
a phosphorimager, and the amounts (in arbitrary units) were illustrated in bars. Quantitative presentation of the ratio between the distal and
proximal G-free cassettes was illustrated in the bottom panel.back prior to preincubation (Figure 4D) or during
elongation (Figure 4E), The latter experiment was carried
out in order to exclude the possibility that the presence of
P-TEFb during preincubation and initiation steps may
cause phosphorylation of RNAPII or DSIF and thus
prevent the eﬀect of NELF on elongation. As expected,
P-TEFb was critical for the stimulatory activity of DSIF
(Figure 4D, lanes 4 to 6). When P-TEFb was absent,
NELF cooperated with DSIF to repress elongation
(Figure 4E, lanes 3 to 6), and the addition of P-TEFb
after the start of transcription alleviated this repression
(Figure 4E, lanes 7 to 10). Importantly, with P-TEFb
added back, the full-length transcripts were synthe-
sized to similar extent regardless of the presence of
Flag
AB
RNAPII
CDK8
CDK9
mock
∆P-TEFb
dpl. P1.0 conc.
P1.0 conc. ∆P-TEFb
pG5MLP
His-DSIF
± Flag-NELF
0 +2
± P-TEFb
NTPs
(min) –40
stop at indicated time
D
C
E
Figure 4. NELF does not aﬀect the positive activity of DSIF. (A) Silver staining of puriﬁed Flag-NELF. (B) In vitro transcription assays were carried
out as described for Figure 1E, except that His-DSIF was added to reactions of lanes 2 to 4 and 8 to 10; Flag-NELF was added to the reactions of
lanes 3 to 6 and 9 to 12 and DRB was added to the reactions of lanes 7 to 12. Numbers on the left indicate the positions of markers (nucleotides).
(C) Western blot analysis of CDK9, RNAPII and CDK8 in the concentrated P1.0 fraction either mock depleted or depleted with anti-CDK9
antibody. (D) In vitro transcription assays were carried out as described in Figure 1E, except that P-TEFb- or mock-immunodepleted concentrated
P1.0 fraction was used. P-TEFb was added back prior to incubation as indicated. (E) In vitro transcription assays were carried out using P-TEFb-
depleted concentrated P1.0 fraction, His-DSIF and pG5MLP as a template. His-DSIF and Flag-NELF were combined with the mixture during the
pre-incubation, while P-TEFb was added 2min after addition of nucleotides, as shown in the diagram.
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DSIF-induced promoter-proximal pausing has no inﬂu-
ence on the subsequent DSIF- and P-TEFb-induced
processive elongation.
DSIFis critical toGal4-VP16-mediated activation in vivo
To investigate the role of DSIF in transcriptional
activation in vivo, we used a reporter gene assay in HeLa
cells, in which the expression of the reporter gene is
controlled by Gal4-VP16. In this system, we predicted that
if Gal4-VP16-mediated transcriptional activation involves
the positive activity of DSIF, depletion of the large
subunit of DSIF, hSpt5, would reduce expression of the
reporter gene. We transfected HeLa cells with a plasmid
expressing a short hairpin RNA (shRNA) targeting hSpt5,
together with Gal4-VP16 or Gal4DBD expression plas-
mids, and a luciferase reporter plasmid with Gal4-binding
sites upstream of the promoter. Western blot analysis
showed an 80% decrease in the amount of hSpt5 in cells
transfected with shRNA No. 1, compared to cells
transfected with a control plasmid, 72h after transfection
(Figure 5A). A second shRNA targeting a diﬀerent
sequence in hSpt5 similarly knocked down hSpt5 protein
levels in cells, indicating that the eﬀect of shRNAs was
gene-speciﬁc. We used shRNA No. 1 in the following
experiments. Knockdown of hSpt5 caused a signiﬁcant
reduction in Gal4-VP16-activated expression of the
reporter gene 72h after transfection (Figure 5B, upper
panel), consistent with in vitro results that DSIF coop-
erates with Gal4-VP16 to achieve high-level activation.
In contrast, when cells were transfected with a plasmid
encoding Gal4DBD instead of Gal4-VP16, knockdown of
hSpt5 had little eﬀect on the low-level expression of the
reporter gene (Figure 5B, lower panel).
A
C
B
D
Figure 5. Gal4-VP16-activated transcription requires Spt5. (A) HeLa cells were transfected with one of the three constructs: a control plasmid,
pBS-U6-hSpt5 (No. 1) or pBS-U6-hSpt5 (No. 2). Proteins were isolated from cells 72h post-transfection, and subjected to Western blot analysis
using an antibody against hSpt5 (upper panel). p54/nrb was examined as loading control (lower panel). (B) HeLa cells were co-transfected with a
reporter plasmid carrying Gal4-binding sites and the luciferase gene, pCG-GAL4-VP16 (upper panel) or pCG-GAL4 (lower panel), and an shRNA-
expressing plasmid for control (blue) or hSpt5 knockdown (KD) cells (red). Transfected cells were collected at the indicated times after transfection,
and luciferase activity was measured. Data represents the means   standard deviation (SD) of three independent experiments. (C) Reporter gene
assays were performed as described for (B), except that the indicated amounts of a Gal4 (1–94) expression plasmid were co-transfected with the
Gal4VP16 expression plasmid into HeLa cells. Luciferase activity 72h after transfection is shown. Data represents the means SD of three
independent experiments. (D) Based on the results in panel C, the eﬀects of hSpt5 knockdown on the reporter gene expression were calculated.
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conditions where transcriptional activity is induced, but
not for transcription under basal conditions. To examine
the requirement for DSIF more precisely, we adjusted the
expression levels of the luciferase reporter gene by
co-expressing varying amounts of Gal4DBD with Gal4-
VP16. The Gal4DBD(1–94) is able to bind DNA
templates, and is believed to interfere with Gal4-VP16-
mediated activation in a competitive manner. As shown in
Figure 5C, expression of increasing amounts of Gal4DBD
diminished expression of the reporter gene in both hSpt5
knockdown and control cells, suggesting that Gal4-VP16-
mediated activation was competitively suppressed by
Gal4DBD. Note that the expression level of the luciferase
reporter gene in hSpt5 knockdown cells approached that
of control cells with increasing amounts of Gal4DBD.
Figure 5D shows the ratio of luciferase activity in hSpt5
knockdown cells relative to control cells, illustrating
quantitatively the results in Figure 5C. These results
indicated that diﬀerent levels of transcription have
diﬀerent requirements for DSIF.
Together, the results of both in vivo and in vitro assays
showed that transcription at a higher level imposes a
stronger requirement for DSIF.
DISCUSSION
In the current study, we demonstrated that DSIF acts
cooperatively with a DNA-binding activator, Gal4-VP16,
to activate transcription in vitro, by reducing pausing.
Using a reporter gene assay in cultured HaLa cells, we
showed that Spt5 knockdown reduced Gal4-VP16-
induced expression of the reporter gene, but had a
negligible eﬀect on expression in the absence of the
activation domain. The requirement for DSIF was dimin-
ished by suppressing transcriptional activation through
expression of a DNA-binding competitor of Gal4-VP16,
Gal4DBD, suggesting that DSIF is an elongation factor
targeting sites of active transcription, but has minimal
involvement in basal transcription. In addition, we
showed that DSIF exerts its positive eﬀect within a short
time-frame from initiation to elongation but does not
aﬀect initiation, and that NELF is not involved in the
positive activity of DSIF. These results elucidate the role
of DSIF in transcriptional activation, giving additional
weight to the correlation between DSIF and sites of active
transcription, and support the idea that transcription
at high-levels has a stronger requirement for DSIF. Thus,
expression of genes that are undergoing active transcrip-
tion is likely to be aﬀected more by the loss of function
of DSIF compared to genes undergoing basal-level
transcription.
Regulation oftranscription elongation and kinetics of
activation
Our data suggests that Gal4-VP16 stimulates transcription
initiation but is unable to overcome pausing during
elongation, and that DSIF is required to reduce pausing,
thereby cooperating with the activator to promote
transcription.
As to why DSIF would be required only for high-level
transcription, it is possible that when transcription occurs
at a very low level, preinitiation or initiation may be the
rate-limiting step, and therefore, the eﬃciency of the
subsequent elongation step (i.e. the presence or absence
of DSIF) may not contribute substantially to the overall
rate of RNA synthesis. Upon transcriptional induction,
however, the rates of preinitiation and initiation may
be elevated by the action of activators, and the eﬃciency
of the elongation step may become critical to the overall
rate of RNA synthesis. Although it is not clear to what
extent this model is applicable to cellular genes, it has been
shown that expression of c-fos has similar requirements
for DSIF as the reporter gene studied here (9). The general
applicability of this model may be tested by carrying out
microarray analysis of DSIF knockdown samples pre-
pared under various induction conditions.
How then does DSIF play important roles in activated
transcription? The following explanations may account
for the signiﬁcant requirement for DSIF: (a) activators
may directly recruit DSIF to target genes, making the
eﬀect of DSIF signiﬁcant; (b) activators may indirectly
recruit DSIF through other proteins; (c) activators may
cause a modiﬁcation of DSIF which enhances its positive
activity.
As to the ﬁrst and second possibilities, several groups
have reported the recruitment of DSIF to various genes,
including heat shock genes, c-fos, junB and MAP kinase
phosphotase-1 (MKP-1), upon extracellular stimuli
(9–11,37). However, no evidence so far has been found
to show direct physical interactions between DSIF and
activators. We also failed to detect any interaction
between Gal4-VP16 and DSIF using a GST pull-down
assay or a cross-linked immunoprecipitation experiment
(data not shown). Moreover, Gal4-VP16 neither increased
the stimulatory eﬀect of DSIF (Figure 3D) nor changed
the time-frame of DSIF recruitment (Figure 3B), suggest-
ing that Gal4-VP16 may not directly recruit DSIF.
Since DSIF binds to RNAPII (4), DSIF may be recruited
secondarily through its interaction with RNAPII upon
transcriptional induction. This idea is supported by the
observation that the DSIF density changes dynamically
corresponding to similar change of RNAPII around
promoter regions of hsp70, c-fos, junB and MKP-1
during activation (9–11,37).
Methylation of the Spt5 subunit of DSIF may
negatively regulate the association with RNAPII (38).
In contrast, P-TEFb-mediated phosphorylation of Spt5 is
critical for the positive activity of DSIF (9,13). DSIF may
undergo these modiﬁcations during activation of tran-
scription. As to the third possibility, the protein arginine
methyltransferases PRMT1 and PRMT5, which are
capable of methylating Spt5, associate with cytokine-
inducible promoters under basal conditions and disas-
sociate from the promoters after activation (38).
In contrast, P-TEFb has been reported to be recruited to
promoter regions during the activation of transcription
(11,37). Several transcription factors, such as CIITA, NF-
kB, Myc and STAT3, have been shown to interact with
and recruit P-TEFb to target gene promoters (39–42).
During Tat-transactivated HIV transcription, P-TEFb is
Nucleic Acids Research, 2007, Vol. 35, No. 12 4073recruited by Tat to stimulate elongation (43). However, we
did not ﬁnd any interaction between P-TEFb and Gal4-
VP16 in a GST pull-down assay and a cross-linked
immunoprecipitation experiment (data not shown). Yang
et al. (44) have reported that P-TEFb interacts with
Mediator through Brd4, which may be implicated in the
recruitment of P-TEFb. The Mediator is a multiprotein
complex recruited to promoters via activators, including
Gal4-VP16, and serves as a molecular bridge between
activators and RNAPII (45–47). Activators may stimulate
the recruitment of P-TEFb through Mediator to modulate
phosphorylation of the CTD of RNAPII as well as of
DSIF during a post-initiation stage.
DSIFexerts its positive effect within ashort timewindow
frominitiation toelongation
We showed that DSIF was unable to exert its positive
eﬀect in vitro when added to transcription reactions at
later time points. This ﬁnding can be interpreted in several
ways. DSIF may only associate with early elongation
complexes, and may not be able to exert its positive eﬀect
on mature elongation complexes. This may occur in one of
several ways. First, a factor that helps DSIF to enter
transcription complexes, such as Mediator, may not exist
in late elongation complexes. Mediator does not appear to
walk along with the elongation complex to downstream
regions of genes. Rather, it may act as a bridging molecule
between activators and DSIF, and thus may help recruit
more DSIF to activated genes. Functional links between
DSIF and Mediator have been reported recently, although
their physical interaction has not yet known (48). Second,
RNAPII may undergo a conformational change that
inhibits its interaction with DSIF after a speciﬁc time-
frame of DSIF action. Thirdly, other factors recruited at
a later stage of transcription may mask the binding site
on RNAPII that is involved in its interaction with DSIF.
Alternatively, prior incubation of DSIF with transcrip-
tion complexes may be necessary for its action. This model
would involve a slow mechanism of action, such as modi-
ﬁcation of DSIF. Since P-TEFb-mediated phosphoryla-
tion of the CTR of hSpt5 activates the positive activity of
DSIF (9), the time required for this phosphorylation event
may delay the kinetics of DSIF action. Furthermore, since
P-TEFb is prone to be released from transcription
complexes during elongation (49,50), DSIF may not be
phosphorylated eﬃciently in mature elongation complexes
because of the lack of P-TEFb.
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